Edition:
United States

Aptevo Therapeutics Inc (APVO.OQ)

APVO.OQ on NASDAQ Stock Exchange Global Select Market

1.64USD
3:59pm EST
Change (% chg)

$-0.23 (-12.30%)
Prev Close
$1.87
Open
$1.84
Day's High
$1.89
Day's Low
$1.64
Volume
20,844
Avg. Vol
17,040
52-wk High
$6.30
52-wk Low
$1.64

Latest Key Developments (Source: Significant Developments)

Aptevo Therapeutics Q3 Loss Per Share $0.56
Wednesday, 14 Nov 2018 04:02pm EST 

Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.56.Q3 EARNINGS PER SHARE VIEW $-0.57 -- THOMSON REUTERS I/B/E/S.DISCONTINUES CLINICAL DEVELOPMENT OF APVO414 AND OTLERTUZUMAB; SHARPENS FOCUS ON NEXT-GENERATION ADAPTIR PIPELINE.IS ALSO PROGRESSING PLANS TO ADVANCE A SECOND CANDIDATE, APVO210, INTO CLINIC IN Q1 OF 2019.ADVANCES BISPECIFICS APVO436 AND APVO210; ON TRACK TO COMMENCE PATIENT DOSING Q4 2018 AND Q1 2019.HAD CASH, CASH EQUIVALENTS, RESTRICTED CASH, AND SHORT-TERM INVESTMENTS AS OF SEPTEMBER 30, 2018 TOTALING $45.5 MILLION.  Full Article

Aptevo Therapeutics Q1 Loss Per Share $0.63
Thursday, 10 May 2018 09:00am EDT 

Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.63.QUARTERLY TOTAL REVENUES $4.1 MILLION VERSUS $2.1 MILLION.  Full Article

Aptevo Therapeutics Reports 2017 Financial Results And Provides Business Update
Tuesday, 13 Mar 2018 09:02am EDT 

March 13 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.APTEVO - ‍HAD CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AS OF DEC 31, 2017 TOTALING $91.2 MILLION​.  Full Article

Aptevo Therapeutics Announces Plans To Conduct Phase 2 Study Of Otlertuzumab In Peripheral T-Cell Lymphoma
Tuesday, 28 Nov 2017 07:02am EST 

Nov 28 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS ANNOUNCES PLANS TO CONDUCT PHASE 2 STUDY OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA.APTEVO THERAPEUTICS INC- ‍EXPECTS TO FILE 2 IND APPLICATIONS IN 2018 FOR 2 BISPECIFIC ANTIBODY CANDIDATES, APVO436 AND APVO210​.  Full Article

Aptevo Therapeutics files mixed shelf of up to $150 mln
Monday, 13 Nov 2017 06:14am EST 

Nov 13 (Reuters) - Aptevo Therapeutics Inc :Aptevo Therapeutics Inc files for mixed shelf of up to $150 million - SEC filing‍​.  Full Article

Aptevo Therapeutics reports third quarter 2017 financial results
Thursday, 9 Nov 2017 04:30pm EST 

Nov 9 (Reuters) - Aptevo Therapeutics Inc :Aptevo Therapeutics reports third quarter 2017 financial results.Q3 earnings per share $1.77.  Full Article

APTEVO THERAPEUTICS ‍AMENDS TERMS OF CREDIT AGREEMENT
Thursday, 28 Sep 2017 04:45pm EDT 

Sept 28 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS INC - ‍AMENDED TERMS OF A CREDIT AGREEMENT INITIALLY EXECUTED WITH MIDCAP FINANCIAL TRUST IN AUGUST 2016​.APTEVO THERAPEUTICS INC - AS PART OF AMENDMENT, COMPANIES HAVE AGREED TO ELIMINATE OPTION FOR A SECOND TRANCHE OF $15 MILLION.APTEVO THERAPEUTICS INC- AMENDMENT ALLOWS CO TO RETAIN TRANCHE OF $20 MILLION, FUNDED IN AUG 2016.  Full Article

Aptevo Therapeutics signs agreement for up to $74.5 mln to sell Hyperimmune Commercial Products
Thursday, 31 Aug 2017 05:16pm EDT 

Aug 31 (Reuters) - Aptevo Therapeutics Inc ::Aptevo Therapeutics signs agreement for up to $74.5 million to sell hyperimmune commercial products.Aptevo - deal valued at up to $74.5 million, including an upfront payment of $65 million, and an additional potential milestone payment of up to $7.5 million​.Aptevo Therapeutics Inc - co may receive up to $2 million related to collection of certain accounts receivable after closing of deal.Aptevo Therapeutics Inc - ‍agreed to sell its three marketed hyperimmune products, winrho sdf, hepagam b, and varizig, to saol therapeutics​.Aptevo Therapeutics - ‍anticipates that proceeds from sale of hyperimmune products will be used to satisfy current debt obligation to midcap financial​.Aptevo Therapeutics - ‍anticipates that proceeds from sale of hyperimmune products will be used to advance clinical and preclinical adaptir candidates​.  Full Article

Aptevo Therapeutics Inc's reports Q2 loss per share $0.53
Thursday, 10 Aug 2017 09:02am EDT 

Aug 10 (Reuters) - Aptevo Therapeutics Inc ::Aptevo Therapeutics reports second quarter 2017 financial results.Q2 loss per share $0.53.Aptevo Therapeutics Inc - total product sales revenue was $10.8 million for three months ended June 30, 2017, compared to $10.2 million for same period in 2016.  Full Article

Aptevo Therapeutics and Alligator Bioscience to co-develop novel bispecific antibody
Friday, 21 Jul 2017 01:00am EDT 

July 21 (Reuters) - ALLIGATOR BIOSCIENCE AB :APTEVO THERAPEUTICS AND ALLIGATOR BIOSCIENCE ANNOUNCE PLANS TO CO-DEVELOP NOVEL BISPECIFIC ANTIBODY FOR TUMOR-DIRECTED IMMUNOTHERAPY.‍PARTIES WILL JOINTLY OWN AND SHARE EQUALLY IN DEVELOPMENT COSTS ASSOCIATED WITH ADVANCING THIS CANDIDATE THROUGH TO END OF PHASE 2 CLINICAL DEVELOPMENT​.  Full Article